Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell in Florida to podiatrist and vascular surgeons, to treat PAD & CLTI; and to cardiologist to treat Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and Congestive Heart Failure.
The additions to the leadership team are top-tier talent with a proven track record of success in the biopharmaceutical industry:
Croom Lawrence, Chief Commercial Officer: With over 25 years of biotech commercial launch experience, Mr. Lawrence is a veteran in building high performing commercial teams and launching breakthrough therapies. Lawrence has supported 15+ blockbuster launches including global platform brands with multiple indications from Humira ($8B), Rinvoq ($6B), to Dupixent ($3B). Lawrence has generated hundreds of millions in return on marketing investment (ROMI) for Fortune 100 biotech clients, including Merck, BMS, Amgen, and Pfizer/Wyeth. Lawrence has recently been recognized with a PM360 Innovation Award in 2025 for a cognitive testing startup, Acurist.AI.
Sana Farooqui, Fractional Chief Marketing Officer: A seasoned digital strategist and marketing professional, Farooqui will lead the company's digital and social marketing efforts. She will direct messaging across key channels of influence to physicians, patients, and investors, ensuring the VesCell message is impactful, compliant, and aligned with Hemostemix's mission.
Bob Branch, Fractional Vice President, Digital Marketing & Media: With 20+ years of full-funnel medical marketing and media experience from top health communications agencies, Branch will be instrumental in developing and delivering insight-led, omnichannel go-to-market strategies. He has deep experience working with industry leaders like AbbVie, Novartis, Merck on dozens of brands in cardiovascular, neurology, and dermatology, making him an ideal fit to drive media strategies that connect key audiences with VesCell's benefits.
A New Chance to Live Better, Longer
Under Florida's Right-to-Try statute (SB 1768), physicians-including podiatrists, cardiologists, and all specialists treating pain and no-option patients suffering from PAD, CLTI, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, and congestive heart failure can offer VesCell, Hemostemix's patented ACP-01 therapy, to qualifying patients, following informed consent.
- Podiatrists & Vascular Surgeons - Improve Limb Circulation & Prevent Amputation: In three published trials, including Phase II, VesCell generated new circulation to restore blood flow, healed ulcers, and reduced the need for amputation.
- Cardiologists - Restore Cardiac Function: In four published studies of 24, 41, 106 and 53 subjects, VesCell increased ejection fraction, reduced severe angina, improved exercise capacity, and improved quality of life in patients suffering from angina, ischemic and non ischemic dilated cardiomyopathy, respectively.
- (Future) Neurologists - Address Vascular Dementia: Early human results suggest persistent cognitive benefits in vascular dementia for over 10 years in one patient treated with VesCell.
"Hemostemix's new outreach team is tasked with ensuring every eligible Florida practitioner knows the science, the law, and how VesCell works for their patients. This team's collective experience of translating VesCell published outcomes into a clear, compelling messaging for a variety of audiences enables us to reach these cohorts of patients who suffer in pain," stated Thomas Smeenk, CEO.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the contracting of Croom Lawrence, Sana Farooquoi, Bob Branch, in furtherance of market awareness of Hemostemix Inc. and VesCell (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262494
SOURCE: Hemostemix Inc.
